Meta-analysis of 13 trials finds SGLT2 inhibitors reduce heart failure hospitalization in myocardial infarction.
New Drug Combo Lowers Heart Failure Risk After Heart Attack
This meta-analysis synthesizes data from 13 randomized controlled trials involving 22,238 patients with myocardial infarction. It reports th…
Adding a specific diabetes medication to standard heart care may prevent future heart failure after a heart attack.
Review of new-user target trial emulation comparing semaglutide and SGLT2i in U.S. Veterans with type 2 diabetes
Semaglutide Does Not Raise Suicide Risk, Study Finds
This active-comparator, new-user target trial emulation review synthesizes data from 102,361 U.S. Veterans with type 2 diabetes comparing se…
A large new study finds that semaglutide does not increase suicide risk compared to other diabetes drugs, easing fears for millions of patie…
Bayesian network meta-analysis evaluates antidiabetic medications and dementia risk in 4,382,897 patients.
Could diabetes drugs lower dementia risk, or raise it for some patients?
This Bayesian network meta-analysis synthesized data from 28 articles involving 4,382,897 patients to assess antidiabetic drugs and dementia…
Insulin and metformin cut dementia risk, but DPP4 inhibitors may double Alzheimer's risk compared to SGLT2 drugs in diabetes patients.